Asset Details
Do you wish to reserve the book?
Ensuring Access to Injectable Generic Drugs — The Case of Intravesical BCG for Bladder Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ensuring Access to Injectable Generic Drugs — The Case of Intravesical BCG for Bladder Cancer
Do you wish to request the book?
Ensuring Access to Injectable Generic Drugs — The Case of Intravesical BCG for Bladder Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ensuring Access to Injectable Generic Drugs — The Case of Intravesical BCG for Bladder Cancer
2017
Overview
Limits on access to injectable generic drugs force providers to use potentially less effective alternatives, current patients to discontinue therapy, and some new patients to receive more invasive interventions. Yet shortages of important generic drugs remain frequent.
In November 2016, one of the two manufacturers of bacille Calmette–Guérin (BCG) informed health care providers that it planned to exit the market in mid-2017.
1
Intravesical immunotherapy with BCG is the standard of treatment for preventing recurrence and disease progression in high-risk patients with non–muscle-invasive bladder cancer, who account for a substantial minority of patients with newly diagnosed bladder cancer.
2
Yet the past few years have seen intermittent disruptions of the BCG supply. The most recent disruption occurred in 2014, after a plant was temporarily closed because of manufacturing quality issues. The November announcement raises the prospect of a sustained . . .
Publisher
Massachusetts Medical Society
Subject
/ Antineoplastic Agents - economics
/ Antineoplastic Agents - supply & distribution
/ Antineoplastic Agents - therapeutic use
/ Bacillus Calmette-Guerin vaccine
/ BCG
/ BCG Vaccine - supply & distribution
/ BCG Vaccine - therapeutic use
/ Cancer
/ Drugs, Generic - supply & distribution
/ Drugs, Generic - therapeutic use
/ Health Services Accessibility
/ Humans
/ Medicare
